Drug
Teysuno
Teysuno is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
2
50%
Ph phase_1
1
25%
Ph phase_3
1
25%
Phase Distribution
1
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Other(2)
Detailed Status
unknown2
Completed2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (25.0%)
Phase 22 (50.0%)
Phase 31 (25.0%)
Trials by Status
unknown250%
completed250%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine
NCT01845337
unknownphase_1
A Pilot Study of Neoadjuvant TACiE in Locally Advanced Gastric Cancer
NCT05396326
unknownphase_2
Neoadjuvant TACiE in Locally Advanced Gastric Cancer
NCT05346874
completedphase_3
S-1 Versus Capecitabine in the First Line Treatment of MCC Patients.
NCT01918852
Clinical Trials (4)
Showing 4 of 4 trials
NCT01845337Phase 2
Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine
NCT05396326Phase 1
A Pilot Study of Neoadjuvant TACiE in Locally Advanced Gastric Cancer
NCT05346874Phase 2
Neoadjuvant TACiE in Locally Advanced Gastric Cancer
NCT01918852Phase 3
S-1 Versus Capecitabine in the First Line Treatment of MCC Patients.
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4